230 related articles for article (PubMed ID: 26821304)
1. Btk inhibition treats TLR7/IFN driven murine lupus.
Bender AT; Pereira A; Fu K; Samy E; Wu Y; Liu-Bujalski L; Caldwell R; Chen YY; Tian H; Morandi F; Head J; Koehler U; Genest M; Okitsu SL; Xu D; Grenningloh R
Clin Immunol; 2016 Mar; 164():65-77. PubMed ID: 26821304
[TBL] [Abstract][Full Text] [Related]
2. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
5. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
[TBL] [Abstract][Full Text] [Related]
6. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
7. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.
Wang J; Lau KY; Jung J; Ravindran P; Barrat FJ
Eur J Immunol; 2014 Apr; 44(4):1130-6. PubMed ID: 24375473
[TBL] [Abstract][Full Text] [Related]
9. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.
Hutcheson J; Vanarsa K; Bashmakov A; Grewal S; Sajitharan D; Chang BY; Buggy JJ; Zhou XJ; Du Y; Satterthwaite AB; Mohan C
Arthritis Res Ther; 2012 Nov; 14(6):R243. PubMed ID: 23136880
[TBL] [Abstract][Full Text] [Related]
10. [Study on experimental systemic lupus erythematosus mouse model induced by pristane].
Li JZ; Ding J; Merim B; Li HW; Zhang Y; Shen H; Chen XJ; Wang SJ; Wang Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Feb; 27(2):119-22. PubMed ID: 21315035
[TBL] [Abstract][Full Text] [Related]
11. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Chalmers SA; Garcia SJ; Webb D; Herlitz L; Fine J; Klein E; Ramanujam M; Putterman C
Clin Immunol; 2021 Feb; 223():108640. PubMed ID: 33296718
[TBL] [Abstract][Full Text] [Related]
12. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.
Lee PY; Kumagai Y; Li Y; Takeuchi O; Yoshida H; Weinstein J; Kellner ES; Nacionales D; Barker T; Kelly-Scumpia K; van Rooijen N; Kumar H; Kawai T; Satoh M; Akira S; Reeves WH
J Exp Med; 2008 Dec; 205(13):2995-3006. PubMed ID: 19047436
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
14. TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.
Wolf SJ; Theros J; Reed TJ; Liu J; Grigorova IL; Martínez-Colón G; Jacob CO; Hodgin JB; Kahlenberg JM
J Immunol; 2018 Jul; 201(2):393-405. PubMed ID: 29884703
[TBL] [Abstract][Full Text] [Related]
15. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.
Byrne JC; Ní Gabhann J; Stacey KB; Coffey BM; McCarthy E; Thomas W; Jefferies CA
J Immunol; 2013 May; 190(10):5207-15. PubMed ID: 23596312
[TBL] [Abstract][Full Text] [Related]
18. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
Chalmers SA; Doerner J; Bosanac T; Khalil S; Smith D; Harcken C; Dimock J; Der E; Herlitz L; Webb D; Seccareccia E; Feng D; Fine JS; Ramanujam M; Klein E; Putterman C
Sci Rep; 2016 May; 6():26164. PubMed ID: 27192942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
